C1q has spatially distinct functions, with synapse-bound C1q primarily nucleating complement-dependent pruning and microglia-associated C1q potentially modulating effector state through receptor-specific signaling
The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q.
Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)
The strongest spatial model is a split between substrate marking at synapses and state modulation at microglia. The synaptic arm is well grounded, but the microglial surface-signaling arm remains insufficiently demonstrated in CNS microglia and must be tested under complement-defined conditions that isolate location from ligand identity and microglial state.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Stressed Synapse C1q Ligand Exposed"]
B["C1q Deposition Synaptic Tagging"]
C["C3 Cleavage C3b Opsonization"]
D["CR3 Recognition Microglial Receptor"]
E["Synaptic Pruning Phagocytic Engulfment"]
F["Synapse Loss Circuit Disruption"]
G["Cognitive Decline Memory Impairment"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
5 citations5 with PMIDValidation: 0%3 supporting / 2 opposing
✓For(3)
No supporting evidence
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
MECH 5CLIN 0GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Synaptic C1q/C3/CR3 pruning is strongly supported …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling
Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Triage
The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.
The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.
Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC
IF microglia-specific C1q is deleted using Cx3cr1-CreERT2 while neuronal/astrocyte C1q is preserved, THEN microglial activation markers (CD68, MHCII) and pro-inflammatory cytokine profiling will show significant alteration compared to C1q-flox controls, within 3 months post-tamoxifen induction in 5xFAD mice.
pendingconf: 0.55
Expected outcome: Significant reduction in CD68+ phagocytic microglia and decreased IL-1β/TNF-α transcript levels in the hippocampus of microglia-C1q KO mice compared to controls.
Falsified by: No change in microglial activation state or cytokine profile when microglia-specific C1q is deleted; microglial state remains dependent on non-microglial C1q sources only.
Method: Cx3cr1-CreERT2;C1q-flox crossed to 5xFAD amyloid model; tamoxifen induction at 3 months; flow cytometry for CD68/MHCII; NanoString or qPCR for cytokine panel; n≥12 per group.
IF LAIR1 is selectively blocked on microglia via anti-LAIR1 Fab fragments while complement C3 is simultaneously inhibited, THEN microglial process dynamics and arbor complexity will remain altered (indicating receptor-specific signaling) while synaptic complement tagging and engulfment remain suppressed, within 4 weeks of stereotactic antibody infusion.
pendingconf: 0.40
Expected outcome: LAIR1 blockade + C3 inhibition will result in impaired microglial process velocity (>30% reduction) and reduced branch complexity (Sholl analysis) while synaptic PSD95 loss continues at baseline rate, confirming C1q acts through LAIR1 independently of pruning.
Falsified by: Blocking LAIR1 reproduces the same pruning phenotype as C3 inhibition, indicating LAIR1 operates downstream of complement rather than as a separate microglial state modulator.
Method: Stereotactic infusion of anti-LAIR1 Fab (10 μg/μL) + C3 inhibitor (C3aR antagonist, 2 μg/μL) into dorsal hippocampus of adult C57BL/6J mice; two-photon imaging of CX3CR1-GFP microglia at days 0, 7, 14, 28; immunohistochemistry for PSD95 and C1q colocalization at endpoint.